CN
Pipeline
Developing Products
That Are Potent, Enabling,
Novel and Safe
Exosome

Product

Indication

Drug
Discovery

Pre-clinical

IND

Phase I

Phase II

Phase III

BLA

Commer-cialization

MVR-EX101

MVR-EX107

Chronic and Hard-to-treat Diseases

Chronic and Hard-to-treat Diseases

Chronic and Hard-to-treat Diseases

MVR-EX103

MVR-EX104

MVR-EX105

Wound Healing

Pulmonary Fibrosis

Neurodermatitis

Vitiligo

Xerophthalmia

Skincare

Haircare

Fat Reduction

INCI Name Granted
INCI Name expected in 3Q25
INCI Name expected in 3Q25

Technology Edge
Synergistic multi-protein engineering


Breakthrough viral vector modification strategy allowing various administration methods to meet broader clinical scenarios

Targeted delivery

Breakthrough viral vector modification strategy allowing various administration methods to meet broader clinical scenarios

Streamlined Drug Discovery

Breakthrough viral vector modification strategy allowing various administration methods to meet broader clinical scenarios

A company focusing on developing novel
drug delivery vector technology

Phone:0512-66202028

Address:Wuzhong Biology Medical Company Industrial Park Phase 3 Block A2, Guoxiang Street, Wuzhong District, Suzhou, China

Copyright © 2014-2022 IMMVIRA CO.,LTD All Rights Reserved 粤ICP备17163742号-6